Skip to main content
editorial
. 2019 Sep 18;5(3):138–144. doi: 10.1016/S2055-6640(20)30043-1

Supplemental Table S1.

Data included in analysis for 12-week regimens

Drugs Study Study population/subgroups Number of subjects (n) Approved 12-week regimen
DCV ALLY-2 GT1, TN/TE, ±cirrhosis, HCV/HIV co-infection 127 DCV + SOF
EBR and GZR C-EDGE co-infection GT1a without baseline NS5A polymorphisms/GT1b, TN, ±cirrhosis, HCV/HIV co-infection 179 EBR/GZR
C-EDGE TE GT1a without baseline NS5A polymorphisms/GT1b, TE, ±cirrhosis, HCV mono-infection or HCV/HIV co-infection 86 (80 mono-infections, 6 co-infections) EBR/GZR
C-EDGE TN GT1a without baseline NS5A polymorphisms/GT1b, TN, ±cirrhosis 267 EBR/GZR
C-SALVAGE GT1a without baseline NS5A polymorphisms/GT1b, TE, ±cirrhosis 76 EBR/GZR + ribavirin (RBV)
C-SURFER GT1a without baseline NS5A polymorphisms/GT1b, TN/TE, ±cirrhosis, severe renal impairment 115 EBR/GZR
LDV and SOF ION-1 GT1, TN, ±cirrhosis 213 LDV/SOF
ION-2 GT1, TE, without cirrhosis 87 LDV/SOF + RBV
ION-3 GT1, TN, without cirrhosis 216 LDV/SOF
ION-4 GT1, TN/TE, ±cirrhosis, HIV/HCV co-infection 327 Same as mono-infection
GLE and PIB Expedition-1 GT1, TN/TE (PRS), with cirrhosis 90 GLE/PIB
Expedition-4 GT1, TN/TE (PRS), ±cirrhosis, severe renal impairment 55 GLE/PIB
Magellon-1 GT1, TE (NS3/4A PI), ±cirrhosis 25 GLE/PIB
OBV and PTV-r + DAS PEARL-II GT1b, TE, without cirrhosis 91 OBV/PTV-r + DAS
PEARL-III GT1b, TN, without cirrhosis 209 OBV/PTV-r + DAS
PEARL-IV GT1a, TN, without cirrhosis 100 OBV/PTV-r + DAS + RBV
SAPPHIRE-I GT1a, TN, without cirrhosis 322 OBV/PTV-r + DAS + RBV
SAPPHIRE-II GT1a, TE, without cirrhosis 173 OBV/PTV-r + DAS + RBV
TURQUOISE I GT1, TN/TE, ±cirrhosis, HCV/HIV co-infection 25 Same as mono-infection
TURQUOISE III GT1b, TN/TE, with cirrhosis 60 OBV/PTV-r + DAS
SMV COSMOS GT1, TN/TE, without cirrhosis 21 SMV + SOF
OPTIMIST-1 GT1, TN/TE, without cirrhosis 155 SMV + SOF
SOF and VEL ASTRAL-1 GT1, TN/TE, ±cirrhosis 328 SOF/VEL
ASTRAL-5 GT1, TN/TE, ±cirrhosis, HIV co-infection 78 SOF/VEL
SOF, VEL and VOX Polaris-1 GT1, TE, ±cirrhosis 150 SOF/VEL/VOX
Polaris-4 GT1a, TE, ±cirrhosis 36 SOF/VEL/VOX

DAS: dasabuvir; DCV: daclatasvir; EBR: elbasvir; GLE: glecaprevir; GT1: genotype 1; GZR: grazoprevir; HCV: hepatitis C virus; LDV: ledipasvir; NS3/4A PI: HCV NS3/4A protease inhibitor; NS: HCV nonstructural protein; OBV: ombitasvir; PIB: pibrentasvir; PRS: Prior treatment experience with regimens containing (peg) interferon, ribavirin, and/or sofosbuvir, but no prior treatment experience with an HCV NS3/4A PI or NS5A inhibitor; PTV-r: paritaprevir/ritonavir; RBV: ribavirin; SMV: simeprevir; SOF: sofosbuvir; TE: treatment experienced; TN: treatment naive; VEL: velpatasvir; VOX: voxilaprevir.